Lymphocytic Infiltrate of Jessner

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Lymphocytic Infiltrate of Jessner is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • Benign Lymphocytic Infiltrate of the Skin
  • Jessner-Kanof Lymphocytic Infiltration

Disorder Subdivisions

  • None

General Discussion

Jessner lymphocytic infiltrate of the skin is an uncommon disorder that is characterized by benign accumulations of lymph cells in the skin. These small lesions are solid, pink or red in color, and appear on the face, neck, and/or back. Skin surrounding these lesions may be itchy and turn red. The lesions may remain unchanged for several years and then spontaneously disappear, leaving no scars.

Not much is known about this disorder. In fact, there is some difference of opinion as to whether it is distinguishable as a separate condition or represents a stage of some other disorder. Some scientists believe that Jessner lymphocytic infiltrate may be a type of lupus erythematosus tumidus (LET) or discoid lupus erythematosus (DLE).


Symptoms of Jessner lymphocytic infiltrate of the skin include rosy-red, pimple-like eruptions, most commonly on the upper face, cheeks and neck. These lesions are non-scaly in nature and may last for several months. They often expand from the perimeter to form well-defined, smooth, red plaques that vary in diameter up to about one inch.

Occasionally, clear centers will form on the plaques. The skin surrounding the lesions may be reddened and itching. Sensitivity to sunlight may occur but is unusual. Generally, the symptoms disappear after several years but it is possible that they may reappear later. Sometimes, they go through times of getting worse and then getting better again over a period of months or years. Sometimes, they simply go away for no apparent reason.


The exact cause of Jessner lymphocytic infiltrate is not known. Abnormal numbers of lymph cells accumulate in the skin for no clear reason. It is not even clear that this is a disorder distinct from other benign infiltrates of the skin.

Clinical researchers have proposed that Jessner lymphocytic infiltrate may be any one of the following: a distinct entity or disorder in all cases, a distinct entity in some cases but lupus erythematosus (DLE) in others, either DLE or LET (a sub-type of DLE) in all cases, or an initial stage (or an intermediate stage) in the development of some other disorder.

Affected Populations

The incidence or prevalence of Jessner lymphocytic infiltrate of the skin in the United States or Europe is not known. The disorder appears to affect adults before their fifth decade, i.e. younger than 50 years of age. Rarely, it affects children. Although there have been some cases in which it appeared that more than one sibling or family member was affected, no genetic component has been isolated.

Standard Therapies


A skin biopsy, using skin from a recently formed lesion, begins the process of excluding other possible conditions. Further relatively sophisticated tests on the biopsy materials are then undertaken to focus on a final diagnosis.


A period of watchful waiting is recommended to see if the disorder will clear up spontaneously. Treatment includes the use of cosmetics, protection from sunlight, cutting out small lesions surgically, topical medium-potency steroids and other steroids, freezing lesions (cryotherapy), and oral hydroxychloroquine. The use of steroids, topical or systemic, must be monitored carefully, as must the use of hydroxychloroquine.

Investigational Therapies

Information on current clinical trials is posted on the Internet at All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, go to:



Champion RH, Burton JL, Ebling FJG, eds. Textbook of Dermatology. 5th ed. Blackwell Scientific Publications. London, UK; 1992:2103-04.


Poenitz N, Dippel E, Klemke CD, et al. Jessner lymphocytic infiltrate of the skin: a CD8+ polyclonal reactive skin condition. Dermatology. 2003;207:276-84.

Colburn DE, Welch MA, Giles FJ. Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis. Hematology. 2002;7:187-88.

Dippel E, Poenitz N, Klemke CD, et al. Familial lymphocytic infiltration of the skin: histochemical and molecular analysis in three brothers. Dermatology. 2002;204:12-16.

Weber F, Schmuth M, Fritsch P, et al. Lymphocytic infiltration of the skin is a photosensitive variant of lupus erythematosus: evidence by phototesting. Br J Dermatol. 2001;144:292-96.

Kunz M, Henseleit-Walter U, Sorg K, et al. Macrophage marker 27E10 on human keratinocytes helps to differentiate discoid lupus erythematosus and Jessner's lymphocytic infiltrate of the skin. Eur J Dermatol. 1999;9:107-10.

Guillaume JC, Moulin G, Dieng MT et al. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltrate of the skin. Arch Dermatol. 1995;131:1032-35.

Toonstra I, van der Putte SC, de la faille HB, et al. Familial Jessner's lymphocytic infiltrate of the skin, occurring in a father and daughter. Clin Exp Dermatol. 1993;18:142-45.


Zeina B. Jessner Lymphocytic Infiltration of the Skin. emedicine. Last Updated: February 11, 2004. 11pp.


NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases

Information Clearinghouse

One AMS Circle

Bethesda, MD 20892-3675


Tel: (301)495-4484

Fax: (301)718-6366

Tel: (877)226-4267

TDD: (301)565-2966



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223


For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see